**Core Concept**
Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme involved in the nitric oxide (NO) pathway. It is used in the treatment of conditions characterized by pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

**Why the Correct Answer is Right**
Riociguat increases the levels of cyclic guanosine monophosphate (cGMP) by activating sGC, leading to vasodilation and reduced pulmonary vascular resistance. This mechanism is particularly beneficial in PAH and CTEPH, where there is a heightened pulmonary vascular resistance. The increased cGMP levels also have anti-inflammatory properties, which contribute to the therapeutic effects of riociguat.

**Why Each Wrong Option is Incorrect**
**Option A:** While riociguat is used in PAH, it is not a first-line treatment for systemic hypertension. Riociguat's primary mechanism is not related to diastolic blood pressure regulation.
**Option B:** Sildenafil is another sGC stimulator but with a different pharmacokinetic profile and is used primarily in erectile dysfunction and PAH. It is not the correct answer for riociguat's indication.
**Option C:** Bosentan is an endothelin receptor antagonist used in PAH. It has a different mechanism of action compared to riociguat and is not a correct answer.

**Clinical Pearl / High-Yield Fact**
Riociguat is a dual-acting agent that not only stimulates sGC but also has phosphodiesterase type 5 (PDE5) inhibitory activity, which further contributes to its vasodilatory effects.

**Correct Answer:** C. Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).